Phase 2 N=47 A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
Hepatocellular Carcinoma
Primary: Progression Free Survival (PFS) — 2.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage I Prostate Cancer
Primary: Proporation of Subjects Achieving Partial Response, Stable Disease or Progressive Disease Based on PSA Response Rates — 9; 2; 1 Participants
Phase 2 N=500 Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine
Infections, Meningococcal
Primary: Vaccine Response to Meningococcal Antigens for Serum Bactericidal Assay Using Rabbit Complement (rSBA) — 82.7; 69.7; 94.4; 90.3 Percentage of subjects
Phase 2 N=84 Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
Nonalcoholic Steatohepatitis
Primary: The Effect of Obeticholic Acid on Low-density Lipoprotein (LDL) Concentration (Least Squares Mean Change From Baseline at Week 16) — -33.2; -44.27; -39.54; -53.33 mg/dL
Phase 2 N=49 Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Ovarian Carcinoma · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel — 40 mg
Phase 2 N=170 Toradol v. Celecoxib for Postoperative Pain
Pain, Postoperative
Primary: Average Inpatient Postoperative Pain Score — 2.7; 2.4 units on a scale
Phase 2 N=64 A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] — 31.0; 20.0 percentage of participants
Phase 2 N=40 Pilot Trial of Statin Use in Burn Patients
Burns
Primary: Primary Endpoint: Reduction in CRP Level Over Time, Compared to Placebo Measured at Baseline and Days 3, 7, 14. The Mean CRP Levels at Specified Days Will be the…
Phase 2 N=47 Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Phase 2 N=235 Efficacy Of PF-05089771 In Treating Postoperative Dental Pain
Postoperative Dental Pain
Primary: Total Pain Relief From 0 to 6 Hours (TOTPAR[6]) — 6.94; 6.21; 7.00; 14.43 units on a scale
Phase 2 N=36 Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms
Primary: Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent…
Phase 2 N=73 Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
Alzheimer's Disease · Sleep Disorder
Primary: Change From Baseline to 24 Weeks in ADAS-cog — 0.45; 0.19 Scores on a scale
Phase 2 N=24 RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Leukemia · Acute Lymphocytic Leukemia
Primary: Maximum Tolerated Dose [MTD] Determination by Number of Participants With Dose Limiting Toxicity (DLT) — 0; 1 Participants
Phase 2 N=100 Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
Stage IA Breast Cancer · Stage IB Breast Cancer · Stage IIA Breast Cancer
Primary: Recurrence-free Survival — 98 percentage of subjects
Phase 2 N=45 Targeting Inflammation to Treat Cardiovascular Aging
Vascular Stiffness · Endothelial Dysfunction · Diastolic Dysfunction
Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec